Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 1996 results for nice guidelines

  1. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

    HealthTech guidance
    Last updated
    10 August 2022
    View recommendations

    Sections for HTG440

  2. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA543

  3. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

    Technology appraisal guidance
    Last updated
    18 November 2020
    View recommendations

    Sections for TA152

  4. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

    Medtech innovation briefing
    Published
    9 February 2021

  5. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

    Medtech innovation briefing
    Published
    18 January 2017

  6. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887

  7. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    8 January 2026
    View recommendations

    Sections for TA1120

  8. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    decision. It is based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer....

  9. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    decision. It is based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer....

  10. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

    HealthTech guidance
    Published
    23 February 2022
    View recommendations

    Sections for HTG610

  11. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  12. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  13. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

    Medtech innovation briefing
    Published
    30 July 2018

  14. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

    Technology appraisal guidance
    Published
    29 November 2023
    View recommendations

    Sections for TA934

  15. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729